Abstract: A liquid photocurable resin composition contains a (meth)acrylate oligomer component, an alkyl (meth)acrylate monomer component, and a photopolymerization initiator component. The (meth)acrylate oligomer component contains at least one oligomer selected from the group consisting of a polyurethane (meth)acrylate oligomer, a polyisoprene (meth)acrylate oligomer, a polybutadiene (meth)acrylate oligomer, and a polyether (meth)acrylate oligomer that have a weight average molecular weight of 1,000 to 200,000. The photopolymerization initiator contains a molecule cleavage-type photoradical polymerization initiator and a hydrogen-abstracting photoradical polymerization initiator at a ratio by mass of 10:1 to 10:35. The cured resin that is obtained by photoradical polymerization of the photocurable resin composition has a glass transition temperature of ?40 to 20° C. when the composition is cured at a curing ratio of the outermost surface of more than 90%.

Abstract: A liquid photocurable resin composition contains a (meth)acrylate oligomer component, an alkyl (meth)acrylate monomer component, and a photopolymerization initiator component. The (meth)acrylate oligomer component contains at least one oligomer selected from the group consisting of a polyurethane (meth)acrylate oligomer, a polyisoprene (meth)acrylate oligomer, a polybutadiene (meth)acrylate oligomer, and a polyether (meth)acrylate oligomer that have a weight average molecular weight of 1,000 to 200,000. The photopolymerization initiator contains a molecule cleavage-type photoradical polymerization initiator and a hydrogen-abstracting photoradical polymerization initiator at a ratio by mass of 10:1 to 10:35. The cured resin that is obtained by photoradical polymerization of the photocurable resin composition has a glass transition temperature of ?40 to 20° C. when the composition is cured at a curing ratio of the outermost surface of more than 90%.

Abstract: An oxadiazole derivative of formula (I) and a non-toxic salt thereof, 1

Abstract: The present invention provides a prophylactic and therapeutic medicament for ophthalmic diseases, especially ophthalmic inflammatory diseases and corneal ulcer, comprising as an active ingredient a compound represented by the formula (I): or a pharmacologically acceptable salt or hydrate thereof.

Abstract: The present invention relates to certain substituted oxadiazole peptoids and nonpeptoids useful as inhibitors of serine proteases, especially human neutophil elastase (HNE). Compounds of the present invention are useful for the treatment or amelioration of symptoms of adult respiratory distress syndrome, septic shock, and multiple organ failure. Processes mediated by HNE are also implicated in conditions such as arthritis, periodontal disease, glomerulonephritis, and cystic fibrosis.

Abstract: The present invention relates to certain substituted oxadiazole peptoids and nonpeptoids useful as inhibitors of serine proteases, especially human neutophil elastase (HNE). Compounds of the present invention are useful for the treatment or amelioration of symptoms of adult respiratory distress syndrome, septic shock, and multiple organ failure. Processes mediated by HNE are also implicated in conditions such as arthritis, periodontal disease, glomerulonephritis, and cystic fibrosis.

Abstract: The present invention relates to certain substituted oxadiazole peptoids and nonpeptoids useful as inhibitors of serine proteases, especially human neutophil elastase (HNE). Compounds of the present invention are useful for the treatment or amelioration of symptoms of adult respiratory distress syndrome, septic shock, and multiple organ failure. Processes mediated by HNE are also implicated in conditions such as arthritis, periodontal disease, glomerulonephritis, and cystic fibrosis.

Abstract: The present invention relates to certain substituted oxadiazole peptoids and nonpeptoids useful as inhibitors of serine proteases, especially human neutophil elastase (HNE). Compounds of the present invention are useful for the treatment or amelioration of symptoms of adult respiratory distress syndrome, septic shock, and multiple organ failure. Processes mediated by HNE are also implicated in conditions such as arthritis, periodontal disease, glomerulonephritis, and cystic fibrosis.

Abstract: A sulfonamide derivatives of formula (I) ##STR1## a non-toxic salts, an acid addition salts or a solvates thereof which has an inhibitory effect on elastase.

Abstract: A sulfonamide derivatives of formula (I) ##STR1## a non-toxic salts, an acid addition salts or a solvates thereof which has an inhibitory effect on elastase.